Novo Nordisk Set to Launch Late-Stage Trials for Weight Management Drugs
Novo Nordisk has announced plans to initiate late-stage trials for its amycretin injection and oral drugs targeting adults with overweight or obesity. Set to commence in early 2026, the trials aim to assess the efficacy and safety of these treatments in aiding weight management.

Pharmaceutical giant Novo Nordisk announced on Thursday its intention to begin late-stage clinical trials for amycretin injections and oral drugs.
The trials, set to start in the first quarter of 2026, will focus on adults who are overweight or clinically obese.
This initiative reflects the company's commitment to addressing global health challenges related to weight management.
(With inputs from agencies.)
Advertisement
ALSO READ
Global Regulators Invited to Shape Future at IAEA RegCon2026 in Vienna
The Heat Challenge: World Cup 2026 Under Fire
Indian Golf Premier League to Tee Off in January 2026
Trump's 2026 Defense Budget: High-Tech Upgrades Amidst Military Cuts
Britain Unveils Curling Squad for 2026 Milano-Cortina Olympics